Immunotherapy plus chemo versus chemo alone before surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial tests whether adding immunotherapy to chemotherapy before surgery works better than chemotherapy alone for resectable esophageal cancer. The goal is to improve outcomes after tumor shrinkage before the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of thoracic esophageal squamous cell cancer that has spread to certain nearby lymph nodes but no distant metastasis
- Your cancer has not been treated before with any anti-cancer therapy for esophageal cancer
- You must be able to have surgery with an expected complete removal (R0 resection) and have no major surgery-blocking problems
- Your blood counts and organ tests must be high enough (for example, white blood cells, neutrophils, platelets, and blood hemoglobin) and liver/kidney tests must be within limits
- You are generally healthy enough for treatment, with good performance status (ECOG 0 to 1) and age 18 to 75
- You should not have other active cancers, recent heart events, serious infections needing treatment, or conditions that make immunotherapy/chemo unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab), an immune-boosting agent (thymalfasin), and standard chemotherapy given before surgery for esophageal cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests a treatment plan that combines chemotherapy with immunotherapy, followed by surgery, for people whose esophageal or stomach cancer has spread to a few areas (oligometastatic). The goal is to see if this approach can shrink the cancer and improve outcomes.
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
This study looks at people with esophageal squamous cell carcinoma to see how changes in the “tumor neighborhood” may affect how well treatment works before surgery. If you’re eligible, you would receive chemotherapy plus immunotherapy as neoadjuvant (before-surgery) treatment.
This trial tests a treatment plan that combines chemotherapy and immunotherapy before surgery, followed by radiation and immunotherapy after surgery for people with esophageal squamous cell cancer. It aims to see if this approach helps prevent the cancer from coming back.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.